disodium [4-[4-oxo-3-[[1-[12-[4-oxo-2-(4-sulfonatooxyphenyl)quinazolin-3-yl]dodecyl]triazol-4-yl]methyl]quinazolin-2-yl]phenyl]sulfate

ID: ALA4445340

Chembl Id: CHEMBL4445340

PubChem CID: 155517814

Max Phase: Preclinical

Molecular Formula: C43H43N7Na2O10S2

Molecular Weight: 884.01

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  O=c1c2ccccc2nc(-c2ccc(OS(=O)(=O)[O-])cc2)n1CCCCCCCCCCCCn1cc(Cn2c(-c3ccc(OS(=O)(=O)[O-])cc3)nc3ccccc3c2=O)nn1.[Na+].[Na+]

Standard InChI:  InChI=1S/C43H45N7O10S2.2Na/c51-42-36-15-9-11-17-38(36)44-40(31-19-23-34(24-20-31)59-61(53,54)55)49(42)28-14-8-6-4-2-1-3-5-7-13-27-48-29-33(46-47-48)30-50-41(45-39-18-12-10-16-37(39)43(50)52)32-21-25-35(26-22-32)60-62(56,57)58;;/h9-12,15-26,29H,1-8,13-14,27-28,30H2,(H,53,54,55)(H,56,57,58);;/q;2*+1/p-2

Standard InChI Key:  CWLAFFNWGQSHPO-UHFFFAOYSA-L

Associated Targets(Human)

ELANE Tclin Leukocyte elastase (8173 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
F11 Tchem Coagulation factor XI (1733 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
F2 Tclin Thrombin (11687 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
F7 Tchem Coagulation factor VII (948 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
F9 Tchem Coagulation factor IX (922 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
F10 Tclin Coagulation factor X (9693 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KLKB1 Tclin Plasma kallikrein (2047 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Alpha-chymotrypsin (819 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 884.01Molecular Weight (Monoisotopic): 883.2669AlogP: 7.04#Rotatable Bonds: 21
Polar Surface Area: 227.69Molecular Species: ACIDHBA: 15HBD: 2
#RO5 Violations: 3HBA (Lipinski): 17HBD (Lipinski): 2#RO5 Violations (Lipinski): 3
CX Acidic pKa: -2.84CX Basic pKa: 4.69CX LogP: 8.69CX LogD: 3.58
Aromatic Rings: 7Heavy Atoms: 62QED Weighted: 0.05Np Likeness Score: -0.63

References

1. Morla S, Sankaranarayanan NV, Afosah DK, Kumar M, Kummarapurugu AB, Voynow JA, Desai UR..  (2019)  On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients.,  62  (11): [PMID:31074986] [10.1021/acs.jmedchem.9b00379]
2. Boothello RS, Sankaranarayanan NV, Afosah DK, Karuturi R, Al-Horani RA, Desai UR..  (2020)  Studies on fragment-based design of allosteric inhibitors of human factor XIa.,  28  (23.0): [PMID:32992249] [10.1016/j.bmc.2020.115762]

Source